Shares of 89bio, Inc. (NASDAQ:ETNB - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $8.35, but opened at $8.66. 89bio shares last traded at $8.40, with a volume of 142,930 shares changing hands.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the company. UBS Group increased their price target on 89bio from $25.00 to $38.00 and gave the company a "buy" rating in a research report on Friday, January 31st. Citigroup assumed coverage on 89bio in a research report on Thursday. They set a "buy" rating and a $25.00 target price on the stock. Raymond James raised 89bio to a "strong-buy" rating in a research report on Thursday, December 12th. Wolfe Research assumed coverage on 89bio in a research report on Tuesday, February 4th. They set an "outperform" rating on the stock. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of 89bio in a research report on Friday, March 7th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $29.63.
Read Our Latest Stock Report on ETNB
89bio Stock Performance
The stock has a 50 day moving average of $8.79 and a two-hundred day moving average of $8.46. The stock has a market capitalization of $1.21 billion, a PE ratio of -2.85 and a beta of 1.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.66 and a quick ratio of 11.66.
89bio (NASDAQ:ETNB - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.42). Research analysts expect that 89bio, Inc. will post -3.19 EPS for the current fiscal year.
Insider Buying and Selling
In related news, insider Quoc Le-Nguyen sold 10,963 shares of the company's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $6.49, for a total value of $71,149.87. Following the completion of the transaction, the insider now directly owns 271,833 shares in the company, valued at approximately $1,764,196.17. This represents a 3.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Charles Mcwherter purchased 5,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were purchased at an average cost of $6.55 per share, with a total value of $32,750.00. Following the transaction, the director now owns 15,000 shares of the company's stock, valued at $98,250. This trade represents a 50.00 % increase in their position. The disclosure for this purchase can be found here. 2.80% of the stock is currently owned by insiders.
Institutional Investors Weigh In On 89bio
Institutional investors have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of 89bio by 26.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 178,691 shares of the company's stock worth $1,397,000 after buying an additional 37,693 shares during the period. Woodline Partners LP boosted its position in shares of 89bio by 640.1% in the fourth quarter. Woodline Partners LP now owns 394,826 shares of the company's stock worth $3,088,000 after buying an additional 341,479 shares during the period. Stempoint Capital LP purchased a new stake in shares of 89bio in the fourth quarter worth about $4,268,000. Suvretta Capital Management LLC boosted its position in shares of 89bio by 27.7% in the fourth quarter. Suvretta Capital Management LLC now owns 10,202,696 shares of the company's stock worth $79,785,000 after buying an additional 2,211,052 shares during the period. Finally, Sandia Investment Management LP boosted its position in shares of 89bio by 28.5% in the fourth quarter. Sandia Investment Management LP now owns 11,286 shares of the company's stock worth $88,000 after buying an additional 2,500 shares during the period.
89bio Company Profile
(
Get Free Report)
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 89bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 89bio wasn't on the list.
While 89bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
